Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast
Status:
Withdrawn
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to validate the ultrasound scores PsASon22 and PsASon13 in
patients with active psoriatic arthritis undergoing a treatment with Apremilast.
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of Graz
Collaborators:
Celgene Corporation Medical University Innsbruck Medical University of Vienna